Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05622669 | Understanding Patterns of Fatigue in Health and Disease(FATIGUE) | completed | — | 40 | University of AberdeenOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05772546 | Avatrombopag vs. Placebo for CIT in GI Malignancies(ACT-GI) | completed | Phase 2 | 49 | Hanny Al-Samkari, MDOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05838417 | Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study | completed | N/A | 499 | University of Colorado, DenverOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06207006 | E-intervention on Subclinical Fear of Cancer Recurrence | completed | N/A | 49 | The University of Hong KongOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06209996 | A Weight Management Intervention for Overweight Chinese Cancer Survivors | completed | N/A | 102 | The University of Hong KongOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06212817 | Dietary Fiber Before Colorectal Cancer Surgery | completed | N/A | 54 | Wageningen UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06236321 | The Microbrect-FFC Study | completed | N/A | 15 | University of AberdeenOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06506578 | Nausea Induced by Radiation of the Dorsal Vagal Complex for Benign Brain Tumors (NausiCAA)(NausiCAA) | completed | — | 100 | University Hospital, BordeauxOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06664034 | Intervening on Women's Health for Rural Young Cancer Survivors | completed | N/A | 42 | University of California, San DiegoOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07790003 | Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer(DEFINITE) | completed | — | 10 | University of AberdeenOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00601900 | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer | completed | Phase 3 | 394 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT01139476 | Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study | completed | — | 1,892 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01582191 | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02851706 | Natural History of and Specimen Banking for People With Tumors of the Central Nervous System | completed | — | 1,214 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03331250 | Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | completed | Phase 2 | 13 | Massachusetts General HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03366155 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03375242 | Safety and Efficacy of Xalkori ROS1 | completed | — | 97 | PfizerINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03388619 | Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03457948 | Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases | completed | Phase 2 | 32 | Nicholas Fidelman, MDOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04090710 | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer(CYTOSHRINK) | completed | Phase 2 | 66 | Ontario Clinical Oncology Group (OCOG)OTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04558866 | Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)(ExBAT) | completed | Phase 2 | 51 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04787341 | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence(PARERE) | completed | Phase 2 | 213 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05168631 | Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors(NET) | completed | — | 88 | Latin American Cooperative Oncology GroupOTHER | 4 | Aug 28, 2026 | clinicaltrials |
| NCT05298423 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)(KEYVIBE-006) | completed | Phase 3 | 610 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 28, 2026 | clinicaltrials |
| NCT05299125 | Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations(AMIGO-1) | completed | Phase 2 | 54 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05328765 | A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection(ACTION HIV) | completed | — | 369 | Latin American Cooperative Oncology GroupOTHER | 5 | Aug 28, 2026 | clinicaltrials |
| NCT07524777 | Ganoderma Spores Modulate the Gut-Brain Axis | completed | N/A | 300 | Ling ZhiqiangOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07791628 | Electrical Grounding and Sleep Quality in Hospitalised Patients With Cancer | completed | N/A | 25 | Chang Gung Memorial HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793084 | The Effectiveness of the Psychological Care of AI Emotional Companion Assistants Among Patients With Advanced Cancer(AI Cancer) | completed | N/A | 50 | National Yang Ming Chiao Tung UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03131908 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT03521596 | Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS(FIL_BIOWM) | completed | — | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03793140 | A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03949946 | Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations? | completed | — | 40 | University of AberdeenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04222335 | Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients(LUNG-RESIST) | completed | N/A | 47 | University Hospital, ToulouseOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT04540211 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma(SKYSCRAPER-08) | completed | Phase 3 | 461 | Hoffmann-La RocheINDUSTRY | 5 | Aug 27, 2026 | clinicaltrials |
| NCT04943445 | Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers(SMART-KEY) | completed | Phase 2 | 43 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05479812 | Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | completed | Phase 1 | 156 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05644821 | Influence of Electronic Patient Reported Outcomes (ePROMs) in Surgical Therapy for Prostate Cancer on Postoperative Outcome(PRO-P) | completed | N/A | 260 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05754229 | Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy | completed | N/A | 395 | Ismail GögenurOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06014580 | Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil(MADONNA) | completed | — | 276 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06234488 | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | completed | — | 125 | Medical College of WisconsinOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06478043 | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06737692 | Effects of Aerobic and Resistance Exercise Training in Individuals With Cancer Cachexia(Exercise) | completed | N/A | 40 | Dokuz Eylul UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07061197 | Effect of Communicating Structured Benefit and Harm Information in European Patient Leaflets on Individuals' Expectations About Medicines | completed | N/A | 2,101 | London School of Economics and Political ScienceOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07110623 | Real-time Molecular Diagnosis of Oral Precancer(LIP) | completed | — | 40 | King's College LondonOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07663994 | Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control Cohort(HD-DNA) | completed | N/A | 68 | Institut Claudius RegaudOTHER | 1 | Aug 27, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 31, 2026source: clinicaltrials